Losartan Potassium Tablet, Film Coated
Product Images NDC 43547-361

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 43547-361). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25 mg, 90 Tablets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

Losartan Potassium Tablets, USP 25 mg, film-coated tablets in a package containing 90 tablets. The label shows dosage strength and manufacturer details including Solco Healthcare US, LLC as the distributor. Storage instructions specify controlled room temperature and protection from light. The label instructs dispensing with an attached patient information leaflet.*

FDA Label Image

50 mg. 30 Tbalets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07)

Label for Losartan Potassium Tablets, USP 50 mg, film-coated tablets. The package contains 30 scored tablets. The label displays storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd, distributor Solco Healthcare US, LLC, and a note to dispense with an attached patient information leaflet. The NDC code is 43547-361-03.*

FDA Label Image

100 mg, 30 Tablets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 08)

Losartan Potassium Tablets USP 100 mg film-coated tablets packaging label. The label indicates the product is distributed by Solco Healthcare US, LLC, with a package count of 30 tablets. Storage instructions include keeping the container tightly closed and protecting from light, with a temperature range of 20° to 25°C. Manufacturer details from Zhejiang Huahai Pharmaceutical Co., Ltd. are also included.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of losartan potassium, depicting its molecular arrangement with atoms and bonds including potassium ion (K+).*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months for Atenolol and Losartan Potassium. The graph shows Atenolol with a dotted line and Losartan Potassium with a solid line, indicating a 13% adjusted risk reduction in favor of Losartan Potassium (p=0.021).*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between two drugs: Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction data indicating a 25% reduction associated with Losartan Potassium (p=0.001). The x-axis represents study months, and the y-axis represents the percentage of patients with stroke.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol. The chart illustrates hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) events across subgroups based on age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease. Symbols indicate event rates and sample sizes, showing comparative effectiveness between the two medications.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph shows cumulative event rates increasing over time, with Losartan Potassium group having lower event percentages than placebo, indicating a 16.1% risk reduction (p=0.022).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.